Karnon J - Search Results

1

A critique and impact analysis of decision modeling assumptions.

Karnon J, Brennan A, Akehurst R. Karnon J, et al. Med Decis Making. 2007 Jul-Aug;27(4):491-9. doi: 10.1177/0272989X07300606. Med Decis Making. 2007. PMID: 17761961

2

Selecting a decision model for economic evaluation: a case study and review.

Karnon J, Brown J. Karnon J, et al. Health Care Manag Sci. 1998 Oct;1(2):133-40. doi: 10.1023/a:1019090401655. Health Care Manag Sci. 1998. PMID: 10916592 Review.

3

The role of modelling in prioritising and planning clinical trials.

Chilcott J, Brennan A, Booth A, Karnon J, Tappenden P. Chilcott J, et al. Among authors: karnon j. Health Technol Assess. 2003;7(23):iii, 1-125. doi: 10.3310/hta7230. Health Technol Assess. 2003. PMID: 14499052 Free article. Review.

4

Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation.

Karnon J. Karnon J. Health Econ. 2003 Oct;12(10):837-48. doi: 10.1002/hec.770. Health Econ. 2003. PMID: 14508868

5

Commentary on Coyle et al., "The assessment of the economic return from controlled clinical trials".

Karnon J, Brennan A, Chilcott J. Karnon J, et al. Eur J Health Econ. 2003 Sep;4(3):239-40. doi: 10.1007/s10198-003-0191-4. Eur J Health Econ. 2003. PMID: 15609191 No abstract available.

6

Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.

Karnon J, Brennan A, Pandor A, Fowkes G, Lee A, Gray D, Coshall C, Nicholls C, Akehurst R. Karnon J, et al. Curr Med Res Opin. 2005 Jan;21(1):101-12. doi: 10.1185/030079904x18036. Curr Med Res Opin. 2005. PMID: 15881481

7

A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK.

Karnon J, Bakhai A, Brennan A, Pandor A, Flather M, Warren E, Gray D, Akehurst R. Karnon J, et al. Int J Cardiol. 2006 May 24;109(3):307-16. doi: 10.1016/j.ijcard.2005.06.026. Epub 2005 Jul 18. Int J Cardiol. 2006. PMID: 16026869

8

Aromatase inhibitors in breast cancer: a review of cost considerations and cost effectiveness.

Karnon J. Karnon J. Pharmacoeconomics. 2006;24(3):215-32. doi: 10.2165/00019053-200624030-00002. Pharmacoeconomics. 2006. PMID: 16519544 Review.

9

A review and critique of modelling in prioritising and designing screening programmes.

Karnon J, Goyder E, Tappenden P, McPhie S, Towers I, Brazier J, Madan J. Karnon J, et al. Health Technol Assess. 2007 Dec;11(52):iii-iv, ix-xi, 1-145. doi: 10.3310/hta11520. Health Technol Assess. 2007. PMID: 18031651 Free article. Review.

10

Modelling the expected net benefits of interventions to reduce the burden of medication errors.

Karnon J, McIntosh A, Dean J, Bath P, Hutchinson A, Oakley J, Thomas N, Pratt P, Freeman-Parry L, Karsh BT, Gandhi T, Tappenden P. Karnon J, et al. J Health Serv Res Policy. 2008 Apr;13(2):85-91. doi: 10.1258/jhsrp.2007.007011. J Health Serv Res Policy. 2008. PMID: 18416913

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

275 results

Search Page

Filters